Vanguards of Health Care by Bloomberg Intelligence
Vanguards of Health Care by Bloomberg Intelligence
Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.Social links:
Follow the podcast:
Vericel Advances Use of Cell Therapies
Vericel acquired a hidden gem in cartilage repair that other companies had written off, and developed it into a high-growth product that could potentially address a $4 billion market. In this episode of the Vanguards of Health Care podcast, Vericel CEO Nick Colangelo sits down with Matt Henriksson,…
46:32
Moderna’s Hoge on the Next Round of Innovations in mRNA
Dr. Stephen Hoge, Moderna’s head of R&D, joined the Vanguards of Health Care podcast to share his insights on the company’s groundbreaking work in messenger RNA. In this episode, Dr. Hoge and Bloomberg Intelligence’s Sam Fazeli take listeners into an in-depth conversation on how Covid was just the …
46:34
Waltz Health on Rewiring the Pharmaceutical Supply Chain
“We’re here to lower the cost of prescription drugs for every American,” Mark Thierer, CEO of Waltz Health explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Thierer joins BI senior health care analyst Jonathan Palmer to discuss Waltz’s Marketplace Search so…
39:30
GeneDx Betting on the Future of Exome and Genome Testing
“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence’s analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx’s 80% market s…
52:20
Penumbra Not Done Adapting in Thrombectomy
Penumbra keeps a two-page list of key thrombectomy opportunities and technologies to innovate that allows it to keep transforming, presently with its computed-assisted vacuum technology (CAVT) for removing clots from the body, CEO Adam Elsesser explains to Bloomberg Intelligence. In this Vanguards …
42:10
Dexcom's Stelo Expands CGMs to Non-Insulin Type 2
Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down w…
31:22
Enovis Has Heft to Be Nimble in Ortho
Enovis is well positioned in the orthopedic market, combining small-cap focus on product innovation with large-cap functionality, CEO Matt Trerotola tells Bloomberg Intelligence. That includes its commercial team, balance sheet and M&A, which let it penetrate some of the fastest-growing segments. I…
44:47
Ro's Foundational Weight Loss Bet Looks to Build on Consumer Success
When Wegovy was approved in 2021, patients began inquiring about whether Ro could build a product that would give them the “Ro experience” in weight loss: The company went to work at the end of 2021, spent all of 2022 building it, launched in 2023 and is now scaling up, CEO and co-founder Zachariah…
1:00:24
A Butterfly Effect for Ultrasound
Butterfly Network looks to streamline the ultrasound workflow and disrupt the incumbent market with its portable ultrasound technology that uses semiconductors instead of traditional crystals, CEO Joe DeVivo explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, DeViv…
37:44
Included Health Seeks to Deliver More Healthy Days
“People who engage with an Included clinician experienced an average of two additional healthy days per month,” Owen Tripp, CEO of Included Health, explains to Bloomberg Intelligence. Tripp joins BI analyst Jonathan Palmer for this episode of the Vanguards of Health Care podcast for a wide-ranging …
53:20